

# CHANG (CHLOE) SU

[suchang@stanford.edu](mailto:suchang@stanford.edu) | PhD Candidate (Expected June 2024) | <https://www.chloesu.com>

## PROFILE

Highly motivated PhD candidate with high-impact publications and extensive clinical research experience in oncology

- Skilled in clinical study design, epidemiologic methods, biostatistics, scientific writing and communications
- Strong understanding of the drug development process through various roles in clinical science, real world evidence, clinical operations, medical affairs, and business strategy in the industry, as well as managing large observational studies
- Strong desire to work in clinical development as an Epidemiologist/Data Scientist/Clinical Scientist to drive clinical trial design and incorporate innovative and appropriate use of real-world evidence for regulatory decisions

## EDUCATION

**Stanford University School of Medicine**, MS & Ph.D. Epidemiology and Clinical Research 2019 – 2024

- **Dissertation:** Evaluating survival, risk, and screening strategies for long-term lung cancer outcomes: distant metastases and second primary lung cancer | **Advisors:** Dr. Summer Han, Dr. Allison Kurian
- **Key Methods:** competing-risk regression, survival analysis, causal inference (target trial emulation, weighting, cloning)

**UC Los Angeles**, B.S. Molecular, Cell, and Developmental Biology, Minor in Biomedical Research 2013 – 2016

- GPA: 3.98, Summa Cum Laude with College Honors, Phi Beta Kappa Honors Society

## RELEVANT WORK EXPERIENCE

**Stanford School of Medicine | Summer Han Lab | Graduate Student Researcher** 4/2020 – Present

- Designed and emulated target clinical trial for screening of second primary lung cancer among long-term lung cancer survivors (survival  $\geq 5$  years) using population-based SEER-Medicare data with causal inference methods; led to **poster presentation** at the American Association for Cancer Research (AACR, 2024)
- Designed and led evaluation of survival difference among patients with distant metastatic non-small cell lung cancer by metastatic disease type (de novo vs. recurrent) and investigated clinical/biological mechanisms behind survival difference using clinical trial data and electronic health records; led to **poster presentation** at the largest international conference on lung cancer (World Conference on Lung Cancer, WCLC 2021) and **first-author** publication in JAMA Network Open
- Designed and led study evaluating impact of lung cancer screening on downstream incidence of brain metastasis using large clinical trial data using competing risk regression; led to **podium presentation** at WCLC 2020 and **first-author** publication in high impact journal (Journal of Thoracic Oncology).
- Led over 3 collaborative studies as **co-first author** with post-doctoral fellows and biostatisticians to investigate racial disparity in lung cancer screening and prevention/early detection/epidemiology of lung cancer in never-smokers
- Drove methodologic design for 4 collaborations with physicians to investigate comparative effectiveness of therapies and effect of therapies on lung cancer outcomes across Stanford Healthcare and Veteran's Health Administration
- Led a team of 6 to conduct medical chart review and data validation to create a curated, linked database across academic and community health centers in the Bay Area, resulting in lead authorship in over 5 natural language processing projects
- Authored multiple grants in collaboration with PI, resulting in funded R01 grants and foundation grants
- Served as primary TA in 6 graduate courses across epidemiologic methods, biostatistics, statistical programming and data management; prepared course materials, led code review sessions and provided 1:1 assignment feedback

**Genentech, Inc. | Clinical Scientist, Intern (Oncology, GI Franchise)** South San Francisco, CA, 6/2023 – 9/2023

- Led presentation of interim analysis to internal/external stakeholders; supported clinical study report for regulatory filing, new Phase II/Phase III study design and strategic planning for no/no-go decision, protocol amendments, and ICF review
- Led two (proposed and initiated one) real-world data projects cross-functionally on comparative effectiveness of existing therapies using Flatiron data to inform new clinical study design; authored study protocols and performed analysis in R

**ZS Associates | Decision Analytics Associate Consultant, Intern** San Francisco, CA, 6/2021 – 9/2021

- Led creation of medical affairs product/trial launch communication strategy playbook for a major pharmaceutical client; coordinated effort across San Francisco and India teams
- Supported major pharmaceutical clients in clinical development acceleration through using innovative trial designs, patient-centric design thinking and organizational change management in oncology, inflammation, and virology spaces
- Conducted financial modeling, pricing, access and contracting for ophthalmology pipeline products

**Stanford Byers Center for Biodesign | NEXT Fellow, Co-Founder/Product Lead** Palo Alto, CA, 9/2020 – 6/2021

- Biodesign NEXT is awarded to top 3 high performing teams emerging from the Designing for Digital Health course; received 1 year of entrepreneur mentorship and funding to innovate and prototype a new digital health product

- Founded and led product design of a healthcare innovation aimed at improving graduate student mental health and wellbeing; coordinated efforts between UI/UX designer and software engineers to prototype minimally viable product
- Presented product demonstration and pitched to Stanford University leadership for funding to continue development

**Amicus Therapeutics, K.K. | Associate Program Manager** **Tokyo, Japan, 8/2019 – 1/2020**

- Drove strategy and operations for development and commercialization of vestronidase alfa (treatment for MPS VII) in Japan and served as primary contact for 19 members from 6 departments to align project priorities and ensure progress
- Identified risks, conducted situational analysis, and performed budget analysis to aid decision-making while ensuring alignment with overall regional and global company strategies
- Led monthly program meetings across Japan, UK, and US to communicate timeline, potential risks, and immediate goals

**Amicus Therapeutics, K.K. | Medical Affairs Intern** **Tokyo, Japan, 8/2019 – 1/2020**

- Assembled scientific and clinical feedback from physicians/KOLs across Japan regarding Galafold (new drug for Fabry Disease) clinical study results, post-marketing studies and patient education materials
- Independently conducted weekly literature review for latest rare disease-related papers for distribution to both Tokyo and Global Medical Affairs Teams and assessed feasibility of potential Investigator-Initiated Study topic on ER Stress

**UCLA Health Department of Radiology | Denise Aberle Group**

**Staff Research Associate III, Project Manager, Data Manager** **11/2018 – 4/2019**

**Staff Research Associate II, Clinical Research Coordinator** **12/2017 – 11/2018**

- Managed the PCORI Watch the Spot Trial (clinical observational study in early lung cancer detection); implemented study management workflow and led a team of 3 to screen, enroll, perform data entry, and carry out data management
- Managed, supervised, and trained team of 5 to perform data extraction from electronic health records to build the IDx lung cancer patient database (currently over 2000 records) for informatics-based research in early lung cancer detection
- Collaborated with development team to perform data integration from various sources in the IDx database, including the biospecimen database and radiology imaging database to create a centralized database for lung cancer research

## **SELECTED PUBLICATIONS (3 of 5 published manuscripts)**

### **\*Co-first author**

- **Su CC**, Wu JT, Neal JW, Popat RA, Kurian AW, Backhus LM, Nagpal S, Leung AN, Wakelee HA, and Han SS. Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. *J Thorac Oncol.* 2021;16(9):1479-1489. doi:10.1016/j.jtho.2021.05.010
- **Su CC**, Wu JT, Choi E, Myall NJ, Neal JW, Kurian AW, Stehr H, Wood D, Henry SM, Backhus LM, Leung AN, Wakelee HA, and Han SS. Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer. *JAMA Netw Open.* 2023;6(9):e2335813. doi:10.1001/jamanetworkopen.2023.35813
- Choi E\*, **Su CC**\*, Wu JT, Aredo JV, Neal JW, Leung AN, Backhus LM, Lui NS, Marchand LL, Stram DO, Liang SY, Cheng I, Wakelee H, Han SS. Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. *JAMA Netw Open.* 2023;6(11):e2343278-e2343278. doi:10.1001/jamanetworkopen.2023.43278

## **SELECTED AWARDS AND HONORS**

- |             |  |
|-------------|--|
| <b>2021</b> | Community Impact Award (1/18 medical school students awarded for commitment to the campus community through involvement and leadership)  |
| <b>2020</b> | Stanford Biodesign NEXT Award (3 out of 9 teams selected to receive year-long entrepreneurial funding)   |
| <b>2016</b> | Amgen Scholarship (fully-funded summer research program in Kyoto University, Tatsushi Igaki Lab)<br>Amgen Japan Symposium Poster Award (3 <sup>rd</sup> Place out of 50)<br>Amgen Kyoto Symposium Poster Award (Best 2 of 25)<br>UCLA Department of Molecular, Cell, and Developmental Biology Poster Award (Best 3 of approx. 50) |
| <b>2014</b> | Peter Rotter Essay Prize for Humanities Writing (5 selected from 200+ nominees across UCLA campus)   |
| <b>2013</b> | Singapore Ministry of Education Scholarship Recipient (undergraduate full ride with monthly stipend)   |

## **ADDITIONAL DETAILS**

Outside my professional endeavors, I enjoy fostering/caring for animals through animal rescues, water sports (surfing/scuba diving), and working on my yoga teacher certification. Being raised as a third culture kid across 3 different countries and worked in 2 other countries, I am comfortable in multi-cultural settings, fluent in both written and spoken English and Mandarin Chinese, and conversational in Japanese with an N3 certification in the Japanese Language Proficiency Test (JLPT).